Nissanim - 1-25

Sisällys/Contents: 1. ¿Andersen: ham-Mal¿ak. Targum: ¿Abi¿asap. 2. ¿Andersen: Be-¿aharit-jam. 3. ¿Andersen: Tippat ham-majim. & ha-Hol. 4-5. Andersen: Perah qatan. 6. H. Lewe: Perah nipla¿. & Qeren hash-shemesh. 7-8. Maqs Nordo: Siah hash-shoshannim. Targum: Sh.L. Gordon. 9. P. ¿Awwirpuk: ¿Ateret haz-zahab. 10. ¿A. Terje: he-Halil han-nipla¿. Targum: P. ¿Awwirpuk. 11-15. Ma¿asijjot liladim. Targum: Shelomo Berman. 16. Mika Josep Berditshevsqi: Ma¿asijjot we-¿aggadot. 17-18. Herodot: Hekal ra¿meses. ¿al jede: ¿A-S. 19. J.V. Levner: hab-Kotel ham-ma¿arabi. 20. ¿A.L. Ja¿aqubovis: ¿Abraham hak-Kaspi. 21-22. Sha¿ul Tshernihovsqi: Shirim. 23-25. Jishaq J. Qassenelson. Shirim.

Konserttiohjelma 1904-04-25 - Ohjelma

Helsinki 1904

Global surveillance of cancer survival 1995-2009 : analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. METHODS: Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75 000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. INTERPRETATION: International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems. FUNDING: Canadian Partnership Against Cancer (Toronto, Canada), Cancer Focus Northern Ireland (Belfast, UK), Cancer Institute New South Wales (Sydney, Australia), Cancer Research UK (London, UK), Centers for Disease Control and Prevention (Atlanta, GA, USA), Swiss Re (London, UK), Swiss Cancer Research foundation (Bern, Switzerland), Swiss Cancer League (Bern, Switzerland), and University of Kentucky (Lexington, KY, USA).

Sosiologipäivät Tampereella 24.-25.3. : yhteiskunta!?

Artikkeli sisältää koosteen vuoden 2006 Sosiologiapäivien yleisesitelmistä sekä 31 työryhmäraporttia

25-years of biomonitoring in two mediterranean streams (Llobregat and Besos basins, NE Spain)

Biological water quality changes in two Mediterranean river basins from a network of 42 sampling sites assessed since 1979 are presented. In order to characterize the biological quality, the index FBILL, designed to characterize these rivers" quality using aquatic macroinvertebrates, is used. When comparing the data from recent years to older ones, only two headwater sites from the 42 had improved their water quality to good or very good conditions. In the middle or low river basin sites or even in headwater localities were river flow is reduced, the important investment to build up sewage water treatment systems and plants (more than 70 in 15 years) allowed for a small recovery from poor or very poor conditions to moderate water quality. Nevertheless still a significant number (25 %) of the localities remain in poor conditions. The evolution of the quality in several points of both basins shows how the main problems for the recovery of the biological quality is due to the water diverted for small hydraulic plants, the presence of saline pollution in the Llobregat River, and the insufficient water depuration. In the smaller rivers, and specially the Besòs the lack of dilution flows from the treatment plants is the main problem for water quality recovery.